Phase I/II Trial of Paclitaxel with Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) with Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors Academic Article uri icon

Overview

MeSH Major

  • Carboplatin
  • Ifosfamide
  • Neoplasms, Germ Cell and Embryonal
  • Paclitaxel

abstract

  • TI-TIC was active in relapsed germ cell tumors but treatment-emergent chronic renal impairment, possibly from overlapping ifosfamide and carboplatin, preclude its further use. TI-CE, consisting of 2¬†cycles of TI with 3 cycles of HD CE remains the standard of care HD chemotherapy regimen at Memorial Sloan Kettering Cancer Center.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5012646

Digital Object Identifier (DOI)

  • 10.1016/j.clgc.2015.05.003

PubMed ID

  • 26072101

Additional Document Info

start page

  • 453

end page

  • 60

volume

  • 13

number

  • 5